Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 1Ganglioneuroblastoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Magnetic Resonance Spectroscopy 4Doxorubicin 4Cyclophosphamide 4Vincristine 3Topotecan 3Stem Cell Transplantation 3Specimen Handling 3Radiation 3Platinum 3Melphalan 3Isotretinoin 3Congresses as Topic 3Cisplatin 3Busulfan 3Biopsy 33-Iodobenzylguanidine 31,2-diaminocyclohexaneplatinum II citrate 3sargramostim 2etoposide phosphate 2dinutuximab 2Etoposide 2Colony-Stimulating Factors 2Carboplatin 2lorlatinib 1Watchful Waiting 1Thiotepa 1Temozolomide 1Razoxane 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Ganglioneuroblastoma × lorlatinib × Clear all
NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Children's Oncology Group

Phase 3 Recruiting
750 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡